Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Eiger Biopharmaceuticals
Eiger Biopharmaceuticals
(EIGR)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Zokinvy
Lonafarnib
2022-07-18
2023-2024
Progeria
,
Laminopathies
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Lonafarnib
progeria
,
chronic hepatitis d
,
hepatitis d
,
hepatitis b
,
laminopathies
Avexitide
obesity
,
type 2 diabetes mellitus
,
diabetes mellitus
Clemizole
hepatitis c
,
hepatitis
,
hepatitis a
,
colorectal neoplasms
,
colonic polyps
,
adenomatous polyps
,
drug interactions
,
healthy volunteers/patients
,
depression
,
major depressive disorder
,
depressive disorder
,
carcinoma
,
hepatocellular carcinoma
,
liver neoplasms
,
squamous cell carcinoma
,
immunoglobulin light-chain amyloidosis
,
proteostasis deficiencies
,
myoclonic epilepsies
,
seizures
,
fever
,
lennox gastaut syndrome
,
malaria
,
falciparum malaria
,
post-traumatic stress disorders
,
traumatic stress disorders
,
neoplasms
,
lung neoplasms
,
eye abnormalities
,
bone marrow examination
,
knee osteoarthritis
Ubenimex
hypertension
,
pulmonary arterial hypertension
,
familial primary pulmonary hypertension
,
lymphedema
,
ischemic stroke
,
stroke
,
ischemia
,
chronic obstructive pulmonary disease
Ebp921
hepatitis d
,
hepatitis
,
hepatitis a
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use